Patents by Inventor Tetsu Kakutani

Tetsu Kakutani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monoclonal antibody, its immunoreactive fragment and hybridoma
    Patent number: 7067314
    Abstract: It is an object to utilize a novel HSCA-3 antigen occurring in immature hemopoietic stem cells and a monoclonal antibody recognizing said antigen in 1) the immunoassay or flow cytometry involving antibody labeling and 2) the isolation and purification of immature hemopoietic stem cells from human bone marrow cells, umbilical code blood or blood enriched in human hemopoietic stem cells by mobilization with G-CSF. It is directed to a novel HSCA-3 antigen occurring in immature hemopoietic stem cells and to a monoclonal antibody or an immunoreactive fragment thereof which recognizes said antigen.
    Type: Grant
    Filed: June 18, 2002
    Date of Patent: June 27, 2006
    Assignee: Kaneka Corporation
    Inventors: Takaaki Ohara, Kenji Yamashita, Tetsu Kakutani, Seishi Kyoizumi
  • Antigen and monoclonal antibody which recognizes the antigen
    Publication number: 20020197655
    Abstract: It is an object to utilize a novel HSCA-3 antigen occurring in immature hemopoietic stem cells and a monoclonal antibody recognizing said antigen in 1) the immunoassay or flow cytometry involving antibody labeling and 2) the isolation and purification of immature hemopoietic stem cells from human bone marrow cells, umbilical code blood or blood enriched in human hemopoietic stem cells by mobilization with G-CSF.
    Type: Application
    Filed: June 18, 2002
    Publication date: December 26, 2002
    Applicant: KANEKA CORPORATION
    Inventors: Takaaki Ohara, Kenji Yamashita, Tetsu Kakutani, Seishi Kyoizumi
  • Cell adhesion protein, gene coding for the same, process for preparing the same and carrier onto which the same is immobilized
    Patent number: 5556943
    Abstract: A sheep LFA-3 protein and derivertires thereof, and derivertives of a human LFA-3 protein, gene coding for the proteins, and processes for preparing the proteins. Said proteins have high affinity for human T-cells.
    Type: Grant
    Filed: October 24, 1994
    Date of Patent: September 17, 1996
    Assignee: Kanegafuchi Kagaku Kogyo Kabushiki Kaisha
    Inventors: Kenji Yamashita, Takaaki Ohara, Hideo Niwa, Fumio Osakada, Takeshi Fukuchi, Tadahiro Edamura, Tetsu Kakutani
  • Human plasminogen activator variants having amino acids 37-42 substituted and a method for their manufacture
    Patent number: 5407819
    Abstract: A TPA variant with replacement of amino acids is provided. In a typical embodiment, the variant has an amino acid sequence with replacement of the amino acid group consisting of asparagine at the 37th position, serine at the 38th position, glycine at the 39th position, arginine at the 40th position, alanine at the 41st position, and glutamine at the 42nd position from the N-terminus of the amino acid sequence of mature human tissue plasminogen activator.
    Type: Grant
    Filed: April 16, 1992
    Date of Patent: April 18, 1995
    Assignee: Kanegafuchi Kagaku Kogyo Kabushiki Kaisha
    Inventors: Hitoshi Yahara, Tetsuya Nagaoka, Kazuyoshi Yajima, Yasuhiro Inenaka, Keiji Matsumoto, Tetsu Kakutani
  • Lymphotoxin DNA, lymphotoxin expression vector
    Patent number: 4988624
    Abstract: A chromosomal DNA sequence which codes for human lymphotoxin, a lymphotoxin expression vector which contains a DNA sequence wherein a chromosomal DNA sequence coding for human lymphotoxin and promoter region which functions in animal cell are linked together, lymphotoxin resistant cell line, transformed animal cell culture which is formed by transforming cultured animal cell with a lymphotoxin expression vector which contains a chromosomal DNA sequence coding for human lymphotoxin and, a process for preparing human lymphotoxin, which comprises transforming cultured animal cell with a lymphotoxin expression vector which contains a chromosomal DNA sequence coding for human lymphotoxin, culturing the transformed cell culture to produce human lymphotoxin, and collecting the human lymphotoxin.According to the present invention, LT which is expected for application as the antitumor agent can be produced effectively in a large amount.
    Type: Grant
    Filed: July 3, 1986
    Date of Patent: January 29, 1991
    Assignee: Kanegafuchi Kagaku Kogyo Kabushiki Kaisha
    Inventors: Tetsu Kakutani, Kenji Yamashita, yasuhiro Ikenaka, Hajime Kawaharada, Kiyoshi Watanabe
  • Human interferon-gamma
    Patent number: 4970161
    Abstract: A DNA sequence on which a chromosomal DNA sequence coding for human interferon-.gamma. (HuIFN-.gamma.) and having a TATA box is ligated to a sequence of a promoter. Cell cultures transformed with said DNA revealed a higher expression of HuIFN- than cell cultures transformed with a DNA which does not have such TATA box. When transformed with said DNA, cell cultures produced HuIFN-.gamma. in a serum free medium. Transformed cell cultures derived from blood cells of HuIFN-.gamma. resistant human cell-line also could produce HuIFN-.gamma..
    Type: Grant
    Filed: January 19, 1988
    Date of Patent: November 13, 1990
    Assignee: Kanegafuchi Kagaku Kogyo Kabushiki Kaisha
    Inventors: Tetsu Kakutani, Keiji Matsumoto, Hiroyuki Maruyama, Kaku Nakagawa, Shinichi Yokota, Hideo Niwa, Katsuhiro Shinjo, Hajime Kawaharada, Kiyoshi Watanabe